Table 1.

Clinical and molecular features of advanced colorectal cancer treated with combination chemotherapy including gefitinib

Case no.Age/SexGefitinib dose (mg)ChemotherapyBest response to therapyEGFRKRASBRAFEGFR IHC*p-AKT1 IHCp53 IHCp21 IHCp27 IHC
167/F250IFLPRWTc.38G>AWT3NNNN
252/F500IFLSWTWTWT2NPPN
339/M500IFLSWTc.38G>AWT2NNPN
466/F250IFLPRWTc.38G>AWT2NNPP
551/M250IFLPRWTWTWT1NNPP
659/M500IFLNot evaluableWTWTc.1799T>A3NPPP
757/M250IFLSc.2170G>AWTWT1NPPP
868/M250IFLPRWTWTWT2NPNP
956/M250IFLPRWTWTWT2NPNP
1049/M500IFLSWTWTWT1NPPP
1158/M250IFLPRWTWTWT1PNPP
1245/M250IFLPRWTWTWTNPNP
1346/M250IFLPRWTc.38G>AWT2NPNN
1464/M500IFLSWTc.35G>AWT0PPNP
1562/F500FOLFIRI§SWTc.34G>AWT1NPPP
1631/M250FOLFIRI§SWTWTWT1NPNP
1741/M250FOLFIRI§SWTc.34G>AWT1PPPP
1838/M250FOLFIRI§PRWTWTWT1NPNP
1946/M500FOLFIRI§SWTWTWT0NPP
2083/M250FOLFIRI§Not evaluableWTc.35G>TWT2NPPP
2163/M250FOLFIRI§PRWTWTWT2NPNP
2241/M500FOLFIRI§SWTWTWT0PPPN
2367/M250IFLSc.2203G>A germline polymorphismWTWT1NPPP
2457/F250FOLFIRI§SWTWTWT2PPPP
2560/M250FOLFIRI§PRWTWTWT1NNNP
2666/F250FOLFIRI§SWTc.34G>AWT2PPPN
2738/F250FOLFIRI§SWTc.35G>AWT2NPPN
2843/F250IFLS2NNNN
2959/M250FOLFIRI§PDWTWTc.1799T>APPN
3051/M250FOLFIRI§PRWTWTWT1NPPN
3179/F250FOLFIRI§SWTWTWT0NPNN
  • NOTE: —, no result.

    Abbreviations: IHC, immunohistochemistry; IFL, bolus 5-FU, leucovorin, and irinotecan; PR, partial response; WT, wild-type; N, negative; S, stable disease; P, positive; FOLFIRI, infusional 5-FU, leucovorin, and irinotecan; PD, progressive disease.

  • * IHC results are 0, negative; 1, weak positive; 2, positive; and 3, strong positive.

  • 5-FU 500 mg/m2, leucovorin 20 mg/m2, irinotecan 125 mg/m2, days 1 and 8 of a 21-day cycle.

  • 5-FU 400 mg/m2, leucovorin 20 mg/m2, irinotecan 100 mg/m2, days 1 and 8 of a 21-day cycle.

  • § 5-FU bolus 400 mg/m2, leucovorin 200 mg/m2, irinotecan 180 mg/m2, infusional 5-FU 2.4 g/m2 over 46 hours, repeated every 2 weeks.